Drug Repurposing Guidebook

Building Block I449

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	Platforms
References	REPO4EU https://repo4.eu https://cordis.europa.eu/project/id/101057619
Description	The Euro-Global Platform for Mechanism-based Drug Repurposing provides support in bioinformatics, target identification, disease agnostic development, IP strategies, regulatory advice from low precision drug therapy to high precision curative therapy through real-world data, Artificial Intelligence and a platform offering every step from lab to phase II clinical. The support is performed by experienced experts from diverse backgrounds such as data scientists, CEO of biotech companies, researchers, clinicians, policy officers, drug developers, health economists etc...
Category	Supporting tools
Type of BB	Development resource
Geographical scope	Europe
Availability	Researchers from academia and industry from countries inside and outside of the European Union
Scope of use	Offer services and develop tools for repurposed drug development - bioinformatics support for an unmet medical need, a registered compound; - search a mechanism of action; - explore your freedom to operate, need a patenting strategy or regulatory advice; - need a business partner;

ITEM	DESCRIPTION
	- a clinical trial test site for phase I-III, or - support with a business plan
Stakeholders involved	Chemists, Pharmacologists, Biologists, bio-informaticians, AI scientists, regulators, ethics experts, policy makers and drug developers, experts in translational medicine and IP
Enablers/ Requirements	Clinicians Drug developers: Start-ups, Pharmaceutical industries Experts in translational medicine and IP Policy makers, regulatory affairs experts
Output	Develop a generic framework that can be used by anybody who wishes to start a drug repurposing project according to current best practices. Clinical trial, market access for a repurposed drug
Best time to apply and time window	During the drug development process.
Expert tips	The ambition of the platform is to cover the whole development chain from identification of a molecule for a given target to providing scientific and HTA advice, IP services or business support